X4 Pharmaceuticals Inc. (NASDAQ:XFOR) saw an upside of 11.07% to $1.36 after adding $0.14on Wednesday. The 5-day average trading volume is 1,745,902 shares of the company’s common stock. It has gained $1.3400 in the past week and touched a new high 3 times within the past 5 days. An average of 3,477,516 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,259,214.
XFOR’s 1-month performance is -24.30% or -$0.5050 on its low of $0.9500 reached on 08/11/23. The company’s shares have touched a 52-week low of $0.65 and high of $2.58, with the stock’s rally to the 52-week high happening on 06/13/23. YTD, XFOR has achieved 36.46% or $0.3220 and has reached a new high 23 times. However, the current price is down -47.38% from the 52-week high price.
Insider Transactions
XFOR stock investors last saw insider trading activity on Aug 18.Stewart Murray (Interim Chief Medical Officer) most recently sold 130,056 shares at $1.06 per share on Aug 10. This transaction cost the insider $137,859. Chief Financial Officer, Mostafa Adam S., sold 2,641 shares at a price of $1.89 on Jun 30. Then, on Jun 30, Chief Operating Officer DiBiase Mary sold 464 shares at a price of $1.89 per share. This transaction amounted to $877.
Valuation Metrics
XFOR stock has a beta of 0.77. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 3.39.
X4 Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 6.60, with the current ratio over the same period at 6.60. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.47, while the total debt to equity was 0.48.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 61.93% to -$55.71 million, while revenue of -$24.02 million was 56.88% off the previous quarter. Analysts expected XFOR to announce -$0.16 per share in earnings in its latest quarter, but it posted -$0.33, representing a -106.20% surprise. EBITDA for the quarter stood at more than -$25.68 million. XFOR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 105.86 million, with total debt at $36.87 million. Shareholders hold equity totaling $164.43 million.
Let’s look briefly at X4 Pharmaceuticals Inc. (XFOR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 44.81% to suggest the stock is trending Neutral, with historical volatility in this time period at 263.99%.
The stock’s 5-day moving average is $1.2250, reflecting a +15.35% or $0.1750 change from its current price. XFOR is currently trading -26.12% above its 20-day SMA, +46.91% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -42.07% and SMA200 by-30.42%.
Stochastic %K and %D was 34.96% and 30.50% and the average true range (ATR) pointed at 0.1440. The RSI (14) points at 41.77%, while the 14-day stochastic is at 41.95% with the period’s ATR at 0.1470. The stock’s 9-day MACD Oscillator is pointing at 0.0367 and -0.0856 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for X4 Pharmaceuticals Inc. (NASDAQ: XFOR), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for XFOR stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate XFOR as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is XFOR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.60 and a high of $5.00, with their median price target at $3.50. Looking at these predictions, the average price target given by analysts is for X4 Pharmaceuticals Inc. (XFOR) stock is $3.64.
